Next-Generation Ocular Implants

PolyActiva’s pipeline of ocular implants with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy for eye care professionals treating patients with a wide range of ocular diseases.

Latanoprost FA SR Ocular Implant

Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension
Clinical Investigation Stage: Phase II

Micro implant.
Sustained drug release.

The Target Product Profile for the Latanoprost FA SR Ocular Implant, currently under development, aims to deliver the following clinical benefits:

PolyActiva achieved study objectives in completed clinical study (NCT03604328) and interim analysis of ongoing study NCT04060758. The Latanoprost FA SR Ocular implant has not been approved by the U.S. Food and Drug Administration (FDA).

Levofloxacin Ocular Implant

Being developed to reduce the risk of Endophthalmitis following ocular (cataract) surgery
Clinical Investigation Stage: Phase I

Micro implant.
Maximum infection
protection.

The Target Product Profile for the Levofloxacin Ocular Implant, currently under development, aims to deliver the following clinical benefits:

Early clinical studies (NCT04682288) conducted by PolyActiva have met clinical trial objectives.
The Levofloxacin Ocular implant has not been approved by the U.S. Food and Drug Administration (FDA)